Wasatch Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Wasatch Advisors’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-355,886	Closed	-$747K	–	305
2018 Q1	$747K	Buy	+355,886	New	+$763K	0.01%	263

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wasatch Advisors's INFI Position: Q2 2018 in Review

Wasatch Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2018, closing a stake of 355,886 shares — an estimated $747K sold.

Wasatch Advisors first reported a position in INFI in Q1 2018 and held it in 1 quarter. The position peaked at $747K in Q1 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q2 2018.

Wasatch Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Wasatch Advisors sold 355,886 Infinity Pharmaceuticals, Inc. shares in Q2 2018, an estimated $747K.
Wasatch Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
Wasatch Advisors's Infinity Pharmaceuticals, Inc. position peaked at $747K in Q1 2018.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2018.

Based on Wasatch Advisors's 13F filing for Q2 2018, filed 2 Aug 2018.